IQVIA HOLDINGS INC. (IQV)

IQVIA is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, operating through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The company employs approximately 88,000 people across more than 100 countries and leverages IQVIA Connected Intelligence™—combining proprietary data, Healthcare-grade AI™, advanced analytics and domain expertise—to deliver actionable insights built on one of the largest healthcare data collections in the world, including more than 1.2 billion non-identified longitudinal patient records, approximately 64 petabytes of proprietary data from roughly 150,000 suppliers, and information covering about 90% of global pharmaceutical sales. Its Technology & Analytics Solutions segment offers cloud-based SaaS platforms for CRM, compliance, real-world evidence, and commercial operations, along with analytics, consulting, and country-level market information services.

Research & Development Solutions provides clinical trial project management and monitoring, functional support services, central laboratory and genomic testing, strategic trial design, and patient/site engagement solutions, including its Avacare Clinical Research Network. Contract Sales & Medical Solutions delivers healthcare provider engagement, patient engagement, and medical services to support commercialization of biopharmaceutical products. The company serves a diversified client base of over 10,000 customers, including nearly all top 100 global pharmaceutical and biotechnology firms, along with payers, providers, governments, and other healthcare stakeholders, with no single client representing more than 5% of 2024 revenue.

IQVIA estimates its addressable market at approximately $330 billion, spanning outsourced R&D (~$73 billion outsourced of $155 billion addressable), real-world evidence and connected health (~$85 billion), and technology-enabled commercial operations (~$82 billion), driven by trends such as biopharmaceutical growth, R&D complexity, cost-efficiency pressures, expanding health data sources, and demand for demonstrated therapeutic value. The company competes against a broad set of firms including Accenture, IBM, ICON, Parexel, Syneos Health, IQVIA, PPD (Thermo Fisher), Veeva, and others across its various business lines, and pursues growth through continued innovation in Connected Intelligence, deepening client relationships, expanding into broader healthcare markets, and strategic acquisitions. IQVIA operates under extensive regulatory oversight covering Good Clinical Practice, FDA and international drug/device regulation, data privacy and protection laws, promotional and marketing rules, and laboratory licensing requirements, and maintains a dedicated global privacy program and governance structures—including a Center for Defensible Data and AI and an AI Governance Council—to ensure responsible, compliant use of patient data and artificial intelligence, including compliance with emerging regulations such as the EU AI Act.

The company also emphasizes intellectual property protection for its proprietary methodologies, technologies, and trademarks, and maintains sustainability initiatives organized around People, Public, and Planet pillars.